9 results about "Tamsulosin" patented technology

Eyedrops for suppressing myopia progression containing an α1-blocker. The α1-blocker is one or more substances selected from a group consisting of bunazosin, prazosin, urapidil, silodosin, tamsulosin, doxazosin, terazosin, naftopidil, trimazosin, indoramin, alfuzosin, moxisylyte, and corynanthine, or pharmaceutically acceptable salts thereof.

the present invention relates to a bilayer tablet for oral administration comprising (1) a first modified release layer comprising tamsulosin or a pharmaceutically acceptable salt thereof and a matrix forming polymer and (2) a second immediate release layer comprising solifenacin or a pharmaceutically acceptable salt thereof and at least one water-insoluble diluent, wherein the tablet is optionally film coated.

In some aspects thereof, the present invention discloses compositions and methods for treating premature ejaculation utilizing tamsulosin at a 0.2 milligram dose administered orally or transdermally every 48 hours. Tamsulosin functions as a selective antagonist of alpha-1a and 1b adrenergic as well as 5HT1A serotonergic receptors implicated in seminal emission pathways. The quantity and frequency of dosing provides an optimal degree of reversible receptor blockade to mildly inhibit sympathetic and serotonergic mediated smooth muscle contraction kinetics governing seminal fluid secretion and transport. This marginally suppresses rate of emission to prolong intercourse without profoundly arresting physiological processes underlying ejaculation.

The invention provides application of tamsulosin or pharmaceutically acceptable salts, esters and hydrates thereof in preparation of drugs for treating skin fibrosis diseases. The application shows that tamsulosin has the effect of slowing down and treating skin fibrosis, has a good application prospect in the aspect of developing the medicine for resisting skin fibrosis diseases, provides a new medicine research and development direction for treating, slowing down and improving skin fibrosis diseases, and has the potential of becoming a new medicine for treating skin fibrosis diseases.

The present invention relates to a sustained-release enteric coating pellet and a method for manufacturing same and, more specifically, to a sustained-release enteric coating pellet and a method for manufacturing same, the sustained-release enteric coating pallet comprising: an inert core; a coating layer of an active ingredient formed on the core; a sustained-release coating layer formed on the coating layer of the active ingredient; and an enteric coating layer formed on the sustained-release coating layer, wherein: the active ingredient is tamsulosin or a pharmaceutically acceptable salt thereof; the sustained-release coating layer comprises a sustained-release agent and a coating stabilizer; the coating stabilizer is polyvinyl alcohol, such that the pellet allows for the sustained release in a continuous and stable manner under enteric conditions and exhibits high reproducibility even when manufactured under various environmental or process conditions.

1. Name of the product in this design: Toothpaste packaging box (Tamusu baking soda). 2. Purpose of this design: For use in the outer packaging of toothpaste. 3. The key design features of this product are the combination of shape and pattern. 4. The picture or photo that best illustrates the key design points: Design 1 3D diagram 1. 5. Design 1 is designated as the basic design.

The invention provides application of darafenib or pharmaceutically acceptable salts, esters and hydrates thereof in preparation of drugs for treating skin fibrosis diseases. The application shows that tamsulosin has the effect of slowing down and treating skin fibrosis, has a good application prospect in the aspect of developing the medicine for resisting skin fibrosis diseases, provides a new medicine research and development direction for treating, slowing down and improving skin fibrosis diseases, and has the potential of becoming a new medicine for treating skin fibrosis diseases.

The invention relates to tamsulosin, in particular to a tamsulosin chiral amine preparation method. According to the method, Fmoc-p-methoxy-L-phenylalanine which is low in cost and can be commercially purchased is used as a raw material, and the Fmoc-p-methoxy-L- The method comprises the following steps: 1) carrying out a reduction reaction on a compound A (Fmoc-p-methoxy-L-phenylalanine) and borane to obtain a compound B; 2) carrying out Appel reaction on the compound B to obtain a compound C; 3) performing hydrodehalogenation reaction on the compound C to obtain a compound D; the invention provides a preparation method of tamsulosin chiral amine, which comprises the following steps: (1) carrying out a sulfonation reaction on a compound D and chlorosulfonic acid, and reacting with ammonia water to obtain a compound E. (5) carrying out deprotection on the compound E to obtain a compound F (tamsulosin chiral amine). The preparation method of tamsulosin chiral amine is a brand new preparation method of tamsulosin chiral amine, and has the advantages of simple route, cheap and easily available raw materials, mild conditions and high reaction yield, and greatly reduces the production cost of tamsulosin.

The present invention relates to a tadalafil oral suspension comprising 0.01-5% w / v of tadalafil, a cyclodextrin, coprocessed microcrystalline cellulose and sodium carboxymethyl cellulose, xanthan gum and water as vehicle. The suspensions are chemically and physically stable and show a dissolution profile equivalent to that of commercial tadalafil film-coated tablets. The tadalafil suspensions are suitable for treating male erectile dysfunction and benign prostatic hyperplasia. The invention also relates to a fixed-dose combination dosage forms comprising said tadalafil suspension and either tamsulosin, in particular, in the form of modified-release pellets, or dutasteride. Said combined forms are useful for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. The invention also relates to a process for the preparation of said tadalafil composition.